These investigations suggest that FLT3, Menin, and BCL2 inhibitors, either alone or in combination with chemotherapy or hypomethylating agents, may offer therapeutic benefits for NUP98‐r AML patients. This evidence concerns the gene NUP98 and acute myeloid leukemia.